India, June 8 -- Monday, Tango Therapeutics, Inc. (TNGX) announced positive initial data from its ongoing Phase 1/2 study of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors daraxonrasib or zoldonrasib.
During the study, patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma or PDAC were treated with a vopimetostat-based combination with either daraxonrasib or zoldonrasib.
The company said that 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieved an objective response. The combination achieved a 100% disease control rate in PDAC patients.
Meanwhile, in the vopimetostat plus zoldonrasib dose escalation arm, patients achieved 52% overall response rate and 74% 6...